471 related articles for article (PubMed ID: 1718648)
21. Malignant melanoma.
Smyth JF
Cancer Chemother Biol Response Modif; 1991; 12():591-602. PubMed ID: 1718379
[No Abstract] [Full Text] [Related]
22. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
23. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
24. New therapies for malignant melanoma.
Hancock B
Practitioner; 1989 Oct; 233(1477):1385-6, 1388. PubMed ID: 2482487
[TBL] [Abstract][Full Text] [Related]
25. [A comparison of the suppressor and cytotoxic activities of the blood mononuclear cells during the adoptive immunotherapy of cancer patients using lymphokine-activated killers with a low dose of recombinant interleukin-2].
Abronina IF; Kupriianova TA; Bolvachova AV; Bykovskaia SN; Dronova OM; Buachidze LI
Biull Eksp Biol Med; 1991 Nov; 112(11):519-21. PubMed ID: 1839773
[TBL] [Abstract][Full Text] [Related]
26. [Cytotoxic T-cell immune response against melanoma antigens].
Ayyoub M
Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
[No Abstract] [Full Text] [Related]
27. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
28. Cellular immunotherapy of cancer.
Yang JC
Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
[TBL] [Abstract][Full Text] [Related]
29. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
30. The role of interleukin-2 in the biotherapy of cancer.
Parkinson DR
Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
[TBL] [Abstract][Full Text] [Related]
31. Despite past disappointments, the future of melanoma therapy appears bright.
Tarhini A
Oncology (Williston Park); 2009 May; 23(6):509, 515. PubMed ID: 19544692
[No Abstract] [Full Text] [Related]
32. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
Tuettenberg A; Schmitt E; Knop J; Jonuleit H
J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
[TBL] [Abstract][Full Text] [Related]
33. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations.
Whiteside TL
In Vivo; 1991; 5(6):553-9. PubMed ID: 1810438
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
Rodolfo M; Salvi C; Bassi C; Rovetta G; Melani C; Colombo MP; Parmiani G
Nat Immun Cell Growth Regul; 1991; 10(6):308-19. PubMed ID: 1787836
[TBL] [Abstract][Full Text] [Related]
35. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
36. T cells take aim at cancer.
Pardoll D
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
[No Abstract] [Full Text] [Related]
37. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy.
Sapoznik S; Ortenberg R; Galore-Haskel G; Kozlovski S; Levy D; Avivi C; Barshack I; Cohen CJ; Besser MJ; Schachter J; Markel G
Cancer Immunol Immunother; 2012 Oct; 61(10):1833-47. PubMed ID: 22441657
[TBL] [Abstract][Full Text] [Related]
38. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
39. Melanoma and immunity.
Rheins LA; Nordlund JJ
Immunol Ser; 1989; 46():769-87. PubMed ID: 2484957
[No Abstract] [Full Text] [Related]
40. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
